Nov. 23, 2021 — ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment Zachary Wright, DVM, DACVIM (Oncology) and Amanda Foskett, DVM, DACVIM (Oncology) to its scientific advisory board.

“I am pleased to add two veterinary oncologists to our advisory board,” said Tammie Wahaus, CEO of ELIAS Animal Health. “Drs. Wright and Foskett bring an invaluable perspective on the advancement of animal cancer treatments.”

Dr. Wright is the Medical Director at Animal Diagnostics Clinic at VCA Hospitals in Dallas, Texas. He received his veterinary medical degree from Texas A&M University and completed a one year rotating small animal internship in medicine and surgery at VCA West Los Angeles Animal Hospital in Los Angeles, California. Dr. Wright completed his residency in small animal oncology at Texas A&M University and became a Diplomate of the American College of Veterinary Internal Medicine-Oncology in 2008. He has published scientific articles and book chapters in small animal oncology and has served in multiple roles within the American College of Veterinary Medicine, including positions on the Board of Regents. Dr. Wright regularly participates in clinical trials at VCA Animal Diagnostic Clinic, including the ECI-OSA-04 canine osteosarcoma clinical trial sponsored by ELIAS.

Dr. Foskett is a veterinary oncologist at Friendship Hospital for Animals in Washington, D.C. She received her veterinary medical degree from the University of Florida. Following veterinary school, she completed a one-year rotating internship in medicine and surgery at Friendship Hospital for Animals, followed by a three-year medical oncology residency program with The Oncology Service. Dr. Foskett has a passion for comparative oncology and small animal internal medicine. She regularly participates in clinical trials exploring new treatments for dogs and cats with cancer, including the ELIAS ECI-OSA-04 trial.

About ELIAS Animal Health
Based in Olathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy is being distributed to veterinarians commercially under 9 CFR 103.3 as an experimental autologous prescription product for the treatment of canine osteosarcoma. The company’s novel therapeutic approach offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. For more information, visit